As demonstrated here, iEVs-335 could lend themselves as a new form of therapeutic intervention in cancers in which genomic interrogation documents a decrease of tumor suppressor miR-335 and/or an increase of SOX4. Optimization of iEVs as vehicles of miRNA therapies in general will further require the addition of simple, cost-effective modalities for precision tissue targeting in vivo upon systemic administration to enhance therapeutic efficacy while reducing off-target effects. The gene discussed is SOX4; the disease is cancer.